GlassScriptPhysician profile
Nanda Channaiah
NPI 1558551036
$3,781.15
in general payments reported to CMS, 2019-2025
27 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $43.15 · 2022: $596 · 2023: $1,326 · 2024: $684 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,575 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,574.93 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $593.42 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $461.39 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $352.15 | 2019-2025 | |
| Abbvie INC. | $340.67 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $266.55 | 2023-2024 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $264.86 | 2022-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $237.77 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $152.13 | 2019-2023 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $144.93 | 2023-2025 | |
| Celgene Corporation | $118.02 | 2019-2023 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.71 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $91.48 | 2023-2025 | Zoryve |
| Incyte Corporation | $88.40 | 2022-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $82.88 | 2024-2025 | |
| Journey Medical Corporation | $73.44 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $60.94 | 2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $53.30 | 2022-2025 | |
| Ucb, INC. | $50.63 | 2022-2025 | Bimzelx |
| Organon LLC | $47.35 | 2025 | Vtama |
| Genentech USA, INC. | $46.57 | 2019-2020 | |
| Aclaris Therapeutics, INC. | $36.47 | 2019 | |
| Botanix Sb INC | $28.19 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $27.29 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.73 | 2025 | Spevigo |
| Promius Pharma LLC | $17.48 | 2019 | |
| Novum Pharma, LLC | $16.82 | 2019 | |
| Dermira, INC. | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanda Channaiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.